TRIGR Therapeutics and ABL Bio Announce Global Oncology Collaboration on Pipeline of Next Generation Therapeutic Antibodies Read more
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months Read more
Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics Read more